Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from PTCT

Sephience Gets FDA Approval, Now A Key Revenue Driver For PTC Therapeutics

The U.S. Food and Drug Administration approved on Monday PTC Therapeutics, Inc.’s (NASDAQ:PTCT) SEPHIENCE (sepiapterin) for children and adult patients with phenylketonuria (PKU).

PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Tops Profit-Taking Zone

PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Tops Profit-Taking Zone

Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.

Investors Business Daily

PTC Therapeutics Signs Exclusive Global License And Collaboration Agreement With Novartis; PTC To Receive Upfront Payment Of $1B, Up To $1.9B In Development, Regulatory And Sales Milestones

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NYSE:NVS), for its

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Dow Jones Futures Fall As Market Rally Retreats Amid Debt-Ceiling Drama; Nvidia Earnings Due

The stock market retreated Tuesday, with many leaders slammed as debt-ceiling talks continue. Nvidia earnings loom large.

Investors Business Daily

Chart of the Day: PTC Therapeutics (PTCT) Upgraded To Buy by Zacks

The Chart of the Day belongs to the biopharmaceutical company PTC Therapeutics (PTCT) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart...

Raymond James Says PTC Therapeutics' CHMP Backing Is 'Under Exceptional Circumstances' What's Next

Last week, PTC Therapeutics Inc's (NASDAQ:PTCT) Upstaza (PTC-AADC; AAV2-based DDC gene therapy) received a CHMP opinion for approval under exceptional circumstances, says Raymond James. It maintains Outperform rating on the stock. The CHMP recommended Upstaza for AADC deficiency (AADCD) patients aged 18 months and older with a severe phenotype. According to the analysts, with the…

Europe's CHMP Backs Approval Of PTC Therapeutics' Gene Therapy In Rare Neurometabolic Disorder

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of PTC Therapeutics Inc's (NASDAQ:PTCT) Upstaza (eladocagene exuparvovec, PTC-AADC). Once ratified by the European Commission, Upstaza will be the first approved disease-modifying treatment for aromatic L-amino acid decarboxylase (AADC) deficiency for patients 18 months and older…

inkl

Read news from The Economist, FT, and more,
with one subscription

PTC Therapeutics's Return On Capital Employed Overview

PTC Therapeutics's Return On Capital Employed Overview

According to data from Benzinga Pro, during Q1, PTC Therapeutics's (NASDAQ:PTCT) reported sales totaled $148.74 million. Despite a 11.54% increase in earnings, the company posted a loss of $126.73 million.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

European Commission

Palo Alto Networks

European Medicines Agency

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

291,396 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play